Literature DB >> 30151089

Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant.

Daoguang Zhang1, Dongdong Tong2, Dezhi Yang3, Jing Sun4, Fenghe Zhang2, Guisen Zhao1.   

Abstract

A series of AKT inhibitors possessing a piperidin-4-yl side chain was designed and synthesized. Some of them showed high AKT1 inhibitory activity and potent anti-proliferative effect on PC-3 prostate cancer cells in the preliminary screening. Further studies revealed the most potent compound, 10h, as a pan-AKT inhibitor. Compound 10h was able to inhibit the cellular phosphorylation of AKT effectively and induce apoptosis of PC-3 cells. It also showed high metabolic stability in human liver microsomes. Preclinical characterization of 10h, a promising lead AKT inhibitor, as a potential anti-prostate cancer therapeutic needs to be further investigated.

Entities:  

Year:  2018        PMID: 30151089      PMCID: PMC6097228          DOI: 10.1039/c8md00197a

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  12 in total

1.  Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.

Authors:  Tao Liu; Wenhu Zhan; Yanming Wang; Liangren Zhang; Bo Yang; Xiaowu Dong; Yongzhou Hu
Journal:  Eur J Med Chem       Date:  2013-12-19       Impact factor: 6.514

2.  Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.

Authors:  Dirk A Heerding; Nelson Rhodes; Jack D Leber; Tammy J Clark; Richard M Keenan; Louis V Lafrance; Mei Li; Igor G Safonov; Dennis T Takata; Joseph W Venslavsky; Dennis S Yamashita; Anthony E Choudhry; Robert A Copeland; Zhihong Lai; Michael D Schaber; Peter J Tummino; Susan L Strum; Edgar R Wood; Derek R Duckett; Derek Eberwein; Victoria B Knick; Timothy J Lansing; Randy T McConnell; Shuyun Zhang; Elisabeth A Minthorn; Nestor O Concha; Gregory L Warren; Rakesh Kumar
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

Review 3.  Recent progress towards clinically relevant ATP-competitive Akt inhibitors.

Authors:  Bayard R Huck; Igor Mochalkin
Journal:  Bioorg Med Chem Lett       Date:  2017-04-29       Impact factor: 2.823

4.  Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.

Authors:  Matt Addie; Peter Ballard; David Buttar; Claire Crafter; Gordon Currie; Barry R Davies; Judit Debreczeni; Hannah Dry; Philippa Dudley; Ryan Greenwood; Paul D Johnson; Jason G Kettle; Clare Lane; Gillian Lamont; Andrew Leach; Richard W A Luke; Jeff Morris; Donald Ogilvie; Ken Page; Martin Pass; Stuart Pearson; Linette Ruston
Journal:  J Med Chem       Date:  2013-02-26       Impact factor: 7.446

Review 5.  Perturbations of the AKT signaling pathway in human cancer.

Authors:  Deborah A Altomare; Joseph R Testa
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

Review 6.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

7.  Identification of inhibitors of protein kinase B using fragment-based lead discovery.

Authors:  Gordon Saxty; Steven J Woodhead; Valerio Berdini; Thomas G Davies; Marcel L Verdonk; Paul G Wyatt; Robert G Boyle; David Barford; Robert Downham; Michelle D Garrett; Robin A Carr
Journal:  J Med Chem       Date:  2007-04-24       Impact factor: 7.446

8.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.

Authors:  D A Cross; D R Alessi; P Cohen; M Andjelkovich; B A Hemmings
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

9.  Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.

Authors:  Yang Liu; Yanzhen Yin; Jingya Zhang; Krystle Nomie; Liang Zhang; Dezhi Yang; Michael L Wang; Guisen Zhao
Journal:  Arch Pharm (Weinheim)       Date:  2016-03-18       Impact factor: 3.751

10.  PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

Authors:  Roberta Ferraldeschi; Daniel Nava Rodrigues; Ruth Riisnaes; Susana Miranda; Ines Figueiredo; Pasquale Rescigno; Praful Ravi; Carmel Pezaro; Aurelius Omlin; David Lorente; Zafeiris Zafeiriou; Joaquin Mateo; Amelia Altavilla; Spyridon Sideris; Diletta Bianchini; Emily Grist; Khin Thway; Raquel Perez Lopez; Nina Tunariu; Chris Parker; David Dearnaley; Alison Reid; Gerhardt Attard; Johann de Bono
Journal:  Eur Urol       Date:  2014-11-04       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.